tiprankstipranks
Exelixis (GB:0IJO)
LSE:0IJO
UK Market
0IJO
Exelixis
RESEARCH TOOLSreports

Exelixis (0IJO) Share Forecast & Price Target

5 Followers
See the Price Targets and Ratings of:

0IJO Analyst Ratings

Hold
15Ratings
Hold
4 Buy
10 Hold
1 Sell
Based on 15 analysts giving stock ratings to
Exelixis
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

0IJO Stock 12 Month Forecast

Average Price Target

$51.92
▼(-7.48% Downside)
Based on 15 Wall Street analysts offering 12 month price targets for Exelixis in the last 3 months. The average price target is $51.92 with a high forecast of $64.00 and a low forecast of $41.00. The average price target represents a -7.48% change from the last price of $56.12.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"36":"$36","65":"$65","43.25":"$43.3","50.5":"$50.5","57.75":"$57.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":64,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$64.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":51.92307692307692,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$51.92</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":41,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$41.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[36,43.25,50.5,57.75,65],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,55.848,56.47507692307692,57.10215384615385,57.72923076923077,58.356307692307695,58.983384615384615,59.610461538461536,60.23753846153846,60.864615384615384,61.491692307692304,62.11876923076923,62.74584615384615,63.37292307692308,{"y":64,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,55.848,55.546082840236686,55.24416568047337,54.94224852071006,54.640331360946746,54.33841420118343,54.03649704142012,53.7345798816568,53.432662721893486,53.13074556213017,52.82882840236686,52.526911242603546,52.22499408284023,{"y":51.92307692307692,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,55.848,54.70584615384615,53.56369230769231,52.42153846153846,51.279384615384615,50.13723076923077,48.99507692307692,47.85292307692308,46.71076923076923,45.568615384615384,44.42646153846154,43.28430769230769,42.142153846153846,{"y":41,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":37.36,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.357,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.291,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.801,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.98,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.53,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.045,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.96,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.095,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.34,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.89,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.43,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.848,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$64.00Average Price Target$51.92Lowest Price Target$41.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Guggenheim Analyst forecast on GB:0IJO
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
―
Hold
―
Reiterated
09/01/26
Guggenheim Remains a Hold on Exelixis (EXEL)
Citi Analyst forecast on GB:0IJO
David Lebowitz
Citi
Citi
$54
Hold
-3.78%
Downside
Reiterated
09/01/26
Exelixis (EXEL) Receives a Hold from BMO Capital
Barclays Analyst forecast on GB:0IJO
Etzer Darout
Barclays
Barclays
$49
Hold
-12.69%
Downside
Reiterated
08/06/26
Barclays Reaffirms Their Hold Rating on Exelixis (EXEL)
RBC Capital Analyst forecast on GB:0IJO
Leonid Timashev
RBC Capital
RBC Capital
$46
Hold
-18.03%
Downside
Reiterated
08/06/26
RBC Capital Sticks to Their Hold Rating for Exelixis (EXEL)
Wells Fargo Analyst forecast on GB:0IJO
Eva Fortea Verdejo
Wells Fargo
Wells Fargo
$49→$50
Hold
-10.91%
Downside
Assigned
08/06/26
Exelixis (EXEL) Gets a Hold from Wells Fargo
Truist Financial Analyst forecast on GB:0IJO
Gregory Renza
Truist Financial
Truist Financial
$56→$52
Hold
-7.34%
Downside
Reiterated
08/06/26
Truist Financial Remains a Hold on Exelixis (EXEL)
Leerink Partners Analyst forecast on GB:0IJO
Andrew Berens
Leerink Partners
Leerink Partners
$52
Hold
-7.34%
Downside
Downgraded
08/06/26
Exelixis downgraded to Market Perform from Outperform at LeerinkExelixis downgraded to Market Perform from Outperform at Leerink
Morgan Stanley Analyst forecast on GB:0IJO
Sean Laaman
Morgan Stanley
Morgan Stanley
$53
Hold
-5.56%
Downside
Reiterated
08/06/26
Morgan Stanley Sticks to Its Hold Rating for Exelixis (EXEL)
Stifel Nicolaus Analyst forecast on GB:0IJO
Stephen Willey
Stifel Nicolaus
Stifel Nicolaus
$47→$51
Hold
-9.12%
Downside
Reiterated
08/06/26
Exelixis (EXEL) Receives a Hold from Stifel Nicolaus
William Blair Analyst forecast on GB:0IJO
Andy Hsieh
William Blair
William Blair
―
Buy
―
Reiterated
08/06/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Ginkgo Bioworks Holdings (NYSE: DNA), Exelixis (NASDAQ: EXEL) and Editas Medicine (NASDAQ: EDIT)
TD Cowen Analyst forecast on GB:0IJO
Yaron Werber
TD Cowen
TD Cowen
$55
Buy
-2.00%
Downside
Reiterated
08/05/26
Exelixis: Buy Rating Reaffirmed on Cabozantinib Resilience, Cost Discipline and Zanzalintinib Upside Despite Near-Term NET Guidance Cut
Bank of America Securities Analyst forecast on GB:0IJO
Jason Gerberry
Bank of America Securities
Bank of America Securities
$41
Sell
-26.94%
Downside
Reiterated
08/05/26
Bank of America Securities Reaffirms Their Sell Rating on Exelixis (EXEL)
Goldman Sachs Analyst forecast on GB:0IJO
Paul Choi
Goldman Sachs
Goldman Sachs
$64
Buy
14.04%
Upside
Reiterated
08/05/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Eli Lilly & Co (NYSE: LLY), Exelixis (NASDAQ: EXEL) and Moderna (NASDAQ: MRNA)
H.C. Wainwright Analyst forecast on GB:0IJO
Robert Burns
H.C. Wainwright
H.C. Wainwright
$56
Buy
-0.21%
Downside
Reiterated
07/02/26
Analysts Offer Insights on Healthcare Companies: Exelixis (NASDAQ: EXEL) and Santhera Pharmaceuticals Holding (Other OTC: SPHDF)
UBS Analyst forecast on GB:0IJO
Ashwani Verma
UBS
UBS
$43→$52
Hold
-7.34%
Downside
Assigned
07/02/26
Analysts Offer Insights on Healthcare Companies: Caris Life Sciences, Inc. (NASDAQ: CAI) and Exelixis (NASDAQ: EXEL)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Guggenheim Analyst forecast on GB:0IJO
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
―
Hold
―
Reiterated
09/01/26
Guggenheim Remains a Hold on Exelixis (EXEL)
Citi Analyst forecast on GB:0IJO
David Lebowitz
Citi
Citi
$54
Hold
-3.78%
Downside
Reiterated
09/01/26
Exelixis (EXEL) Receives a Hold from BMO Capital
Barclays Analyst forecast on GB:0IJO
Etzer Darout
Barclays
Barclays
$49
Hold
-12.69%
Downside
Reiterated
08/06/26
Barclays Reaffirms Their Hold Rating on Exelixis (EXEL)
RBC Capital Analyst forecast on GB:0IJO
Leonid Timashev
RBC Capital
RBC Capital
$46
Hold
-18.03%
Downside
Reiterated
08/06/26
RBC Capital Sticks to Their Hold Rating for Exelixis (EXEL)
Wells Fargo Analyst forecast on GB:0IJO
Eva Fortea Verdejo
Wells Fargo
Wells Fargo
$49→$50
Hold
-10.91%
Downside
Assigned
08/06/26
Exelixis (EXEL) Gets a Hold from Wells Fargo
Truist Financial Analyst forecast on GB:0IJO
Gregory Renza
Truist Financial
Truist Financial
$56→$52
Hold
-7.34%
Downside
Reiterated
08/06/26
Truist Financial Remains a Hold on Exelixis (EXEL)
Leerink Partners Analyst forecast on GB:0IJO
Andrew Berens
Leerink Partners
Leerink Partners
$52
Hold
-7.34%
Downside
Downgraded
08/06/26
Exelixis downgraded to Market Perform from Outperform at LeerinkExelixis downgraded to Market Perform from Outperform at Leerink
Morgan Stanley Analyst forecast on GB:0IJO
Sean Laaman
Morgan Stanley
Morgan Stanley
$53
Hold
-5.56%
Downside
Reiterated
08/06/26
Morgan Stanley Sticks to Its Hold Rating for Exelixis (EXEL)
Stifel Nicolaus Analyst forecast on GB:0IJO
Stephen Willey
Stifel Nicolaus
Stifel Nicolaus
$47→$51
Hold
-9.12%
Downside
Reiterated
08/06/26
Exelixis (EXEL) Receives a Hold from Stifel Nicolaus
William Blair Analyst forecast on GB:0IJO
Andy Hsieh
William Blair
William Blair
―
Buy
―
Reiterated
08/06/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Ginkgo Bioworks Holdings (NYSE: DNA), Exelixis (NASDAQ: EXEL) and Editas Medicine (NASDAQ: EDIT)
TD Cowen Analyst forecast on GB:0IJO
Yaron Werber
TD Cowen
TD Cowen
$55
Buy
-2.00%
Downside
Reiterated
08/05/26
Exelixis: Buy Rating Reaffirmed on Cabozantinib Resilience, Cost Discipline and Zanzalintinib Upside Despite Near-Term NET Guidance Cut
Bank of America Securities Analyst forecast on GB:0IJO
Jason Gerberry
Bank of America Securities
Bank of America Securities
$41
Sell
-26.94%
Downside
Reiterated
08/05/26
Bank of America Securities Reaffirms Their Sell Rating on Exelixis (EXEL)
Goldman Sachs Analyst forecast on GB:0IJO
Paul Choi
Goldman Sachs
Goldman Sachs
$64
Buy
14.04%
Upside
Reiterated
08/05/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Eli Lilly & Co (NYSE: LLY), Exelixis (NASDAQ: EXEL) and Moderna (NASDAQ: MRNA)
H.C. Wainwright Analyst forecast on GB:0IJO
Robert Burns
H.C. Wainwright
H.C. Wainwright
$56
Buy
-0.21%
Downside
Reiterated
07/02/26
Analysts Offer Insights on Healthcare Companies: Exelixis (NASDAQ: EXEL) and Santhera Pharmaceuticals Holding (Other OTC: SPHDF)
UBS Analyst forecast on GB:0IJO
Ashwani Verma
UBS
UBS
$43→$52
Hold
-7.34%
Downside
Assigned
07/02/26
Analysts Offer Insights on Healthcare Companies: Caris Life Sciences, Inc. (NASDAQ: CAI) and Exelixis (NASDAQ: EXEL)
Stocks with the Highest Top Analyst Consensus in the General Sector
STDNStandard Nuclear
SKHYSK Hynix
ITGITG Inc. Class A
LIMENeutron Holdings, Inc.
EROCERock
Find stocks in the General sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Exelixis

3 Months
Robert BurnsH.C. Wainwright
Success Rate
16/19 ratings generated profit
84%
Average Return
+8.77%
Copying Robert Burns's trades and holding each position for 3 Months would result in 84.21% of your transactions generating a profit, with an average return of +8.77% per trade.
1 Year
Robert BurnsH.C. Wainwright
Success Rate
19/19 ratings generated profit
100%
Average Return
+39.39%
Copying Robert Burns's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +39.39% per trade.
2 Years
Robert BurnsH.C. Wainwright
Success Rate
19/19 ratings generated profit
100%
Average Return
+64.96%
Copying Robert Burns's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +64.96% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0IJO Analyst Recommendation Trends

Rating
May 26
Jun 26
Jul 26
Aug 26
Sep 26
Strong Buy
0
0
0
0
0
Buy
9
8
7
6
5
Hold
17
14
15
19
19
Sell
0
1
1
2
1
Strong Sell
0
0
0
0
0
total
26
23
23
27
25
In the current month, 0IJO has received 5 Buy Ratings, 19 Hold Ratings, and 1 Sell Ratings. 0IJO average Analyst price target in the past 3 months is 51.92.
Each month's total comprises the sum of three months' worth of ratings.

0IJO Financial Forecast

0IJO Earnings Forecast

Next quarter’s earnings estimate for 0IJO is $0.89 with a range of $0.76 to $0.96. The previous quarter’s EPS was $0.91. 0IJO beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 50.49% of the time in the same period. In the last calendar year 0IJO has Performed in-line its overall industry.
Next quarter’s earnings estimate for 0IJO is $0.89 with a range of $0.76 to $0.96. The previous quarter’s EPS was $0.91. 0IJO beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 50.49% of the time in the same period. In the last calendar year 0IJO has Performed in-line its overall industry.

0IJO Sales Forecast

Next quarter’s sales forecast for 0IJO is $649.60M with a range of $631.03M to $672.00M. The previous quarter’s sales results were $628.69M. 0IJO beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 63.25% of the time in the same period. In the last calendar year 0IJO has Performed in-line its overall industry.
Next quarter’s sales forecast for 0IJO is $649.60M with a range of $631.03M to $672.00M. The previous quarter’s sales results were $628.69M. 0IJO beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 63.25% of the time in the same period. In the last calendar year 0IJO has Performed in-line its overall industry.

0IJO Stock Forecast FAQ

What is GB:0IJO’s average 12-month price target, according to analysts?
Based on analyst ratings, Exelixis’s 12-month average price target is 51.92.
    What is GB:0IJO’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for GB:0IJO, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Exelixis a Buy, Sell or Hold?
        Exelixis has a consensus rating of Hold, which is based on 4 buy ratings, 10 hold ratings and 1 sell ratings.
          What is Exelixis’s share price target?
          The average share price target for Exelixis is 51.92. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is $64.00 ,and the lowest forecast is $41.00. The average share price target represents -7.48% Decrease from the current price of $56.12.
            What do analysts say about Exelixis?
            Exelixis’s analyst rating consensus is a Hold. This is based on the ratings of 15 Wall Streets Analysts.
              How can I buy shares of Exelixis?
              To buy shares of GB:0IJO, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.